Medindia

X

Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials

Saturday, May 17, 2008 General News J E 4
Advertisement
NEW YORK, May 16 Pulmo BioTech Inc.(OTC Bulletin Board: PLMO.OB) has announced details of the methodology andpurpose of its Phase I Human Trials with its PulmoBind Molecular Imagingtechnology for the diagnosis of Pulmonary Embolism and Pulmonary Hypertension.

The work will be carried out by the Pulmo BioTech subsidiary, PulmoScienceInc., and the title of the work is: "Phase I Study of the Use of PulmoBind forMolecular Imaging of the Pulmonary Circulation."

The study will be a single center, Phase 1 safety and efficacy study of asingle intravenous injection of PulmoBind in human subjects with no history oflung disease.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medicaltechnology and research. Our proven strengths combine extensive commercialexperience and academic credentials. The principal staff members areacknowledged experts in their specialized fields, and work with a broad rangeof investment institutions. Pulmo BioTech's mission is to utilize scientificimagination and drive, together with managerial and financial acumen, to bringinnovative and profitable products to the marketplace to the benefit of allstock holders.

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing anon-invasive Molecular Imaging technique for the diagnosis of PulmonaryEmbolism, Pulmonary Hypertension and Lung Inflammatory diseases under thetrade name PulmoBind.

The company was conceived within the Montreal Heart Institute "MHI" (aworld renowned hospital and educational facility). Jointly owned by MHIsubsidiary Innovacor as the technical and operational partner, Dr. JocelynDupuis (the scientific director and originator of the PulmoBind MolecularImaging technology), and by Pulmo BioTech Inc. as the funding partner,PulmoScience Inc. aims to develop this unique and exciting technology, to fundnecessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worthin excess of $500 million per annum and that, provided Regulatory Approval isachieved, the safety and efficacy of its products could allow it to dominatethat market.

About PulmoBind

PulmoBind uses an intravenously delivered radionuclide tagged moleculewhich specifically bonds to the inner walls of the circulatory system in thelungs, and by the use of an external Gamma Camera allows an image of theintegrity of the blood vessels throughout the lungs to be seen by a diagnosticclinician. PulmoScience is currently undertaking Regulatory Approval for PhaseI Human Trials, and while subsequent results from additional tests might notcorroborate the current results, PulmoScience believes that PulmoBind has thepotential to dominate the market for the diagnosis of Pulmonary Embolism. Inparticular, this belief is driven by PulmoScience's expectations of theimproved safety and efficacy that PulmoBind will offer when compared to thecurrent incumbent nuclear medicine based technology for the diagnosis ofPulmonary Embolism. In addition, early indications are that PulmoBind couldbe highly effective in the early stage diagnosis of Pulmonary Hypertension, acondition for which there is no current front line diagnostic test.

Forward-Looking Statements

Forward-looking statements contained in this and other written and oralreports are made based on known events and circumstances at the time ofrelease, and as such, are subject in the future to unforeseen uncertaintiesand risks. All statements regarding future performance, earnings projections,regulatory approval, events or developments are forward-looking statements. Itis possible that the future performance of the company may differ materiallyfrom current expectations, depending on economic conditions and theuncertainty of regulatory approval. A change in econ
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Industry Executives Finding Value in Shift of Scie...
S
MEDIA ALERT: Medco, Healthways to Open Innovative ...